Hidradenitis suppurativa
HS · Immunology · 2 drugs · 1 indications
Chronic inflammatory skin condition with painful nodules.
Competitive Landscape (2 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Bimzelx | UCB | IL-17A/F inhibitor | Antibody | SC | APPROVED |
| Rinvoq | ABBV | JAK inhibitor | Small molecule | ORAL | APPROVED |
Indications (1)
Upcoming Catalysts
Rinvoq - Vitiligo - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - GCA - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA)CLINICAL
ABBV2026
Rinvoq - HS - Ph3 - DataCLINICAL
ABBV2026
Rinvoq - SLE - Ph3 - DataCLINICAL
ABBV2026
Bimzelx - Commercial Momentum UpdatesCOMMERCIAL
UCB2026
Bimzelx vs Risankizumab - PsA - Head-to-Head DataCLINICAL
UCBH2 2026
Data from Supabase · Updated 2026-03-24